S&P Futures
4,136.75 +6.25 (+0.15%) Dow Futures
34,059.00 +64.00 (+0.19%) Nasdaq Futures
12,573.75 +28.50 (+0.23%) Russell 2000 Futures
1,952.90 +3.00 (+0.15%) Crude Oil
78.33 -0.14 (-0.18%) Gold
1,885.10 -5.60 (-0.30%)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2300 |
| Open | 2.1400 |
| Bid | 2.0800 x 800 |
| Ask | 2.1500 x 1800 |
| Day's Range | 2.0600 - 2.1800 |
| 52 Week Range | 1.3500 - 126.2600 |
| Volume | |
| Avg. Volume | 1,580,544 |
| Market Cap | 27.867M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced Anatoly Dritschilo, M.D., CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
- PR Newswire
Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Chairman and Chief Executive Officer, Anatoly Dritschilo, M.D., CEO, and other Shuttle Pharmaceuticals team members will ring the Nasdaq opening bell on Wednesday, January 18, 2023.
- PR Newswire
Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side effects, announced the issuance of a $4.3 million senior secured convertible note and warrant to an institutional investor. Shuttle Pharmaceuticals will receive initial gross proceeds of $4.0 million. In addition, the four-year warrant to purchase up to approximately 1
